The Pharming Group NV has secured €10 million in new working capital from a group of institutional investors in order to enable it to complete a pivotal Phase 3 US study of its recombinant protein therapy, Ruconest, for hereditary angioedema (HAE). ---Subscribe to MedNous to access this article--- Company News
